AVXL | tickerfilter.com

Fundamental analysis

25%

Profitability 25%

Dept financing 5%

Liquidity 50%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

25.96%

1 Month

19.06%

3 Months

99.45%

6 Months

168.40%

1 Year

21.45%

2 Year

28.64%

Key data

Stock price

$12.24

P/E Ratio

0.00

DAY RANGE

$10.79 - $11.79

EPS

$0.00

52 WEEK RANGE

$3.46 - $12.48

52 WEEK CHANGE

$9.69

MARKET CAP

510.469 M

YIELD

N/A

SHARES OUTSTANDING

84.796 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/25/2024

BETA

2.07

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,598,201

AVERAGE 30 VOLUME

$1,812,159

Company detail

CEO: Christopher U. Missling
Region: US
Website: anavex.com
Employees: 40
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Anavex Life Sciences Corp. engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the. treatment of Alzheimer's disease. The company's drug candidate also comprises ANaVEX 3-71 which is. in Phase I clinical. trial for frontotemporal dementia and other dementia indications.

AVXL - ANAVEX LIFE SCIENCES CORP.